These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38118405)

  • 1. Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers.
    Savary C; Luciana L; Huchedé P; Tourbez A; Coquet C; Broustal M; Lopez Gonzalez A; Deligne C; Diot T; Naret O; Costa M; Meynard N; Barbet V; Müller K; Tonon L; Gadot N; Degletagne C; Attignon V; Léon S; Vanbelle C; Bomane A; Rochet I; Mournetas V; Oliveira L; Rinaudo P; Bergeron C; Dutour A; Cordier-Bussat M; Roch A; Brandenberg N; El Zein S; Watson S; Orbach D; Delattre O; Dijoud F; Corradini N; Picard C; Maucort-Boulch D; Le Grand M; Pasquier E; Blay JY; Castets M; Broutier L
    Cell Rep Med; 2023 Dec; 4(12):101339. PubMed ID: 38118405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.
    Meister MT; Groot Koerkamp MJA; de Souza T; Breunis WB; Frazer-Mendelewska E; Brok M; DeMartino J; Manders F; Calandrini C; Kerstens HHD; Janse A; Dolman MEM; Eising S; Langenberg KPS; van Tuil M; Knops RRG; van Scheltinga ST; Hiemcke-Jiwa LS; Flucke U; Merks JHM; van Noesel MM; Tops BBJ; Hehir-Kwa JY; Kemmeren P; Molenaar JJ; van de Wetering M; van Boxtel R; Drost J; Holstege FCP
    EMBO Mol Med; 2022 Oct; 14(10):e16001. PubMed ID: 35916583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.
    Alcon C; Manzano-Muñoz A; Prada E; Mora J; Soriano A; Guillén G; Gallego S; Roma J; Samitier J; Villanueva A; Montero J
    Cell Death Dis; 2020 Aug; 11(8):634. PubMed ID: 32801295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma.
    Patel AG; Chen X; Huang X; Clay MR; Komorova N; Krasin MJ; Pappo A; Tillman H; Orr BA; McEvoy J; Gordon B; Blankenship K; Reilly C; Zhou X; Norrie JL; Karlstrom A; Yu J; Wodarz D; Stewart E; Dyer MA
    Dev Cell; 2022 May; 57(10):1226-1240.e8. PubMed ID: 35483358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.
    Manzella G; Moonamale DC; Römmele M; Bode P; Wachtel M; Schäfer BW
    Neoplasia; 2021 Sep; 23(9):929-938. PubMed ID: 34329950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engaging Cell Death Pathways for the Treatment of Rhabdomyosarcoma.
    Dobson CC; Langlois S; Grynspan D; Cowan KN; Holcik M
    Crit Rev Oncog; 2016; 21(3-4):221-239. PubMed ID: 27915973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma.
    Kahen E; Yu D; Harrison DJ; Clark J; Hingorani P; Cubitt CL; Reed DR
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):313-23. PubMed ID: 27324022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma.
    Generali M; Satheesha S; Bode PK; Wanner D; Schäfer BW; Casanova EA
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
    Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
    Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
    Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
    Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
    Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
    Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group.
    Ferrari A; Orbach D; Casanova M; van Noesel MM; Berlanga P; Brennan B; Corradini N; Schoot RA; Ramirez-Villar GL; Hjalgrim LL; Alaggio R; Guillen Burrieza G; Safwat A; Cameron AL; van Rijn RR; Minard-Colin V; Zanetti I; Bisogno G; Chisholm JC; Merks JHM
    Cancer; 2023 Aug; 129(16):2542-2552. PubMed ID: 37084075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Derived Organoids of Cholangiocarcinoma.
    Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
    Allen-Rhoades W; Lupo PJ; Scheurer ME; Chi YY; Kuttesch JF; Venkatramani R; Meyer WH; Mascarenhas L
    Cancer Med; 2023 May; 12(9):10222-10229. PubMed ID: 37016270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Maru Y; Tanaka N; Itami M; Hippo Y
    Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for pediatric soft-tissue sarcomas.
    Casanova M; Ferrari A
    Expert Opin Pharmacother; 2011 Mar; 12(4):517-31. PubMed ID: 21306288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience.
    Vaarwerk B; Mallebranche C; Affinita MC; van der Lee JH; Ferrari A; Chisholm JC; Defachelles AS; De Salvo GL; Corradini N; Minard-Colin V; Morosi C; Brisse HJ; McHugh K; Bisogno G; van Rijn RR; Orbach D; Merks JHM
    Cancer; 2020 Feb; 126(4):823-831. PubMed ID: 31750944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
    Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.